Bionomics to enter clinical trials for cancer stem cell drug candidate

Bionomics Limited (ASX:BNO, ADR:BMICY) has revealed the U.S. Food and Drug Administration has accepted an investigational new drug application (IND) for its anti-cancer agent which targets cancer stem cells. This paves the way for a clinical trial in …

[Read the full article here]

Comments are closed.